AZILSARTAN Drug Patent Profile
✉ Email this page to a colleague
Which patents cover Azilsartan, and when can generic versions of Azilsartan launch?
Azilsartan is a drug marketed by Lupin and Alkem Labs Ltd and is included in two NDAs.
The generic ingredient in AZILSARTAN is azilsartan kamedoxomil; chlorthalidone. There are six drug master file entries for this compound. Two suppliers are listed for this compound. Additional details are available on the azilsartan kamedoxomil; chlorthalidone profile page.
AI Deep Research
Questions you can ask:
- What is the 5 year forecast for AZILSARTAN?
- What are the global sales for AZILSARTAN?
- What is Average Wholesale Price for AZILSARTAN?
Summary for AZILSARTAN
| US Patents: | 0 |
| Applicants: | 2 |
| NDAs: | 2 |
| DailyMed Link: | AZILSARTAN at DailyMed |
US Patents and Regulatory Information for AZILSARTAN
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Lupin | AZILSARTAN MEDOXOMIL | azilsartan kamedoxomil | TABLET;ORAL | 214489-001 | Jul 20, 2022 | AB | RX | No | No | ⤷ Start Trial | ⤷ Start Trial | ⤷ Start Trial | |||
| Alkem Labs Ltd | AZILSARTAN MEDOXOMIL AND CHLORTHALIDONE | azilsartan kamedoxomil; chlorthalidone | TABLET;ORAL | 217490-002 | Jan 21, 2025 | AB | RX | No | No | ⤷ Start Trial | ⤷ Start Trial | ⤷ Start Trial | |||
| Lupin | AZILSARTAN MEDOXOMIL | azilsartan kamedoxomil | TABLET;ORAL | 214489-002 | Jul 20, 2022 | AB | RX | No | No | ⤷ Start Trial | ⤷ Start Trial | ⤷ Start Trial | |||
| Alkem Labs Ltd | AZILSARTAN MEDOXOMIL AND CHLORTHALIDONE | azilsartan kamedoxomil; chlorthalidone | TABLET;ORAL | 217490-001 | Jan 21, 2025 | AB | RX | No | No | ⤷ Start Trial | ⤷ Start Trial | ⤷ Start Trial | |||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
